Clinical trials: Creutzfeldt-Jakob Syndrome
Alpha-Thalassemia, Beta-Thalassemia
FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
FLOWER is a completely virtual, nationwide, real-world observational study to collect, annotate, standardize, and report clinical data for rare diseases.
- Conditions
- Alpha-Thalassemia, Beta-Thalassemia, Amyloidosis, Amyotrophic Lateral Sclerosis
- Trial name
- NCT06539169
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- xCures
Creutzfeldt-Jakob Disease (CJD) | Prion Disease
CLIME-CJD: A Multimodal Study
Creutzfeldt-Jakob disease (CJD) is a rare and rapidly progressive neurological disorder. This study aims to describe and summarize the key features of CJD by looking back at medical records of patients who were diagnosed with CJD…
- Trial name
- NCT07589283
- Testing
- No Interventions
- Where
- China
- Volunteers
- 150 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Ebola Virus Disease, Marburg Virus Disease
Evaluation of Safety, Tolerability and Immune Responses of Ebola-S and Marburg Vaccines in Healthy Adults
Primary Objective: To evaluate the safety and tolerability of cAd3-EBO-S and cAd3 Marburg vaccines when administered Intramuscular (IM) at a dose of 1 x 10^11 particle units (PU) to healthy adults.
- Trial name
- NCT04723602
- Testing
- cAd3-Marburg, cAd3-EBO-S
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Albert B. Sabin Vaccine Institute
Prion Disease
A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)
This study will test a Regeneron drug called ALN-6457 ("study drug") to see if it can help treat Prion Disease (PrD). In PrD, the prion protein folds into an abnormal shape.
- Trial name
- NCT07832370
- Testing
- ALN-6457
- Volunteers
- 60 people
- Sponsor
- Regeneron Pharmaceuticals
Creutzfeldt-Jakob Syndrome
The Role of the Coagulation Pathway at the Synapse in Prion Diseases
The study hypothesis is that that the deleterious effect of prions on the brain may be mediated (at least partially) by activation of serine proteases involved in the coagulation system.
- Trial name
- NCT02480725
- Testing
- collect CSF (Cerebrospinal fluid) sample
- Volunteers
- 50 people
- Sponsor
- Sheba Medical Center
Prion Disease
PrP-targeting siRNA Safety & Mechanism Study
The purpose of this trial is to evaluate safety, tolerability, pharmacokinetics and pharmacodynamic impact of PrP-siRNA in symptomatic prion disease patients and in pre-symptomatic adults at genetic risk for prion disease.
- Trial name
- PRiSM (NCT07444580)
- Testing
- PrP-siRNA
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Broad Institute of MIT and Harvard
Human Immunodeficiency Virus, Hepatitis B
Notification of Donors With Positive Microbiology Markers
Each year around 200 blood donors in the UK are found to be infected with blood-borne diseases (HIV, hepatitis B, hepatitis C, and HTLV), while several others have been identified as having an increased risk of variant…
- Conditions
- Human Immunodeficiency Virus, Hepatitis B, Hepatitis C, Human T-lymphotropic Virus I & II
- Trial name
- NCT01050881
- Where
- United Kingdom
- Volunteers
- 217 people
- Sponsor
- NHS Blood and Transplant
Creutzfeldt-Jakob Disease (CJD) | Prion Disease
Teleneurology Assessment Program for Creutzfeldt-Jakob Disease
This observational study uses secure videoconference visits to follow people with Creuztzfeldt-Jakob disease (CJD) over time. The study collects information about participants' symptoms, neurological function, thinking and…
- Trial name
- TAPCJD (NCT07840547)
- Testing
- Teleneurology Assessment
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University Hospitals Cleveland Medical Center
Dementia, Dementia, Vascular
Promoting Goals-of-Care Discussions for Patients With Memory Problems and Their Caregivers
The goal of this clinical trial is to improve communication among clinicians, patients with memory problems, and their family members.
- Conditions
- Dementia, Dementia, Vascular, Mixed Dementias, Alzheimer Disease
- Trial name
- PICSI-M (NCT05596760)
- Testing
- Jumpstart Guide
- Where
- 3 sites in United States
- Volunteers
- 1,802 people
- Sponsor
- University of Washington
Creutzfeldt-Jakob Disease (CJD)
A Natural History Study of Preclinical Genetic Creutzfeldt-Jakob Disease (CJD)
Creutzfeldt-Jakob Disease (CJD) is the most common prion disease in humans causing a rapidly progressive neurological decline and dementia and is invariably fatal.
- Trial name
- NHS_CJD (NCT05746715)
- Where
- Israel
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Tel-Aviv Sourasky Medical Center
Prion Disease
PRION-1: Quinacrine for Human Prion Disease
PRION-1 aims to assess the activity and safety of Quinacrine (Mepacrine hydrochloride) in human prion disease. It also aims to establish an appropriate framework for the clinical assessment of therapeutic options for human prion…
- Trial name
- NCT00104663
- Testing
- Quinacrine
- Where
- United Kingdom
- Volunteers
- 160 people
- Sponsor
- Medical Research Council
CJD (Creutzfeldt Jakob Disease), Prion Diseases
OBSERVE: Biomarkers in Individuals at Risk for Prion Disease
We are doing this research to identify biomarkers in individuals who are at-risk for familial prion disease. We hope to use these biomarkers to predict timing of disease onset in pre-symptomatic individuals and to guide the…
- Conditions
- CJD (Creutzfeldt Jakob Disease), Prion Diseases, GSS, FFI
- Trial name
- NCT05124392
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Massachusetts General Hospital
Creutzfeldt-Jakob Disease
CJD (Creutzfeldt-Jakob Disease) Quinacrine Study
The purpose of this clinical trial is to determine the effectiveness of the medication quinacrine on survival in sporadic Creutzfeldt-Jakob disease (sCJD).
- Trial name
- NCT00183092
- Testing
- Quinacrine
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- University of California, San Francisco
Creutzfeldt-Jakob Disease
Efavirenz for the Treatment of Creutzfeldt-Jakob Disease
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group clinical trial designed to evaluate the efficacy and safety of efavirenz in patients with Creutzfeldt-Jakob disease (CJD).
- Trial name
- NCT07482085
- Testing
- Efavirenz
- Where
- China
- Volunteers
- 246 people
- Sponsor
- Xuanwu Hospital, Beijing
Creutzfeldt Jakob Disease
Evaluation of Diagnostic Criteria for Creutzfeldt Jakob Disease
Clinicians know little about Creutzfeldt Jakob disease, and they are not proficient in the diagnostic criteria of Creutzfeldt Jakob disease, so it is easy to misdiagnose or delay the diagnosis.
- Trial name
- NCT04944732
- Testing
- laboratory examination, auxiliary examination, pathological results
- Volunteers
- 30 people
- Sponsor
- Peking University Third Hospital